GPR139

GPR139
Identifiers
AliasesGPR139, GPRg1, PGR3, G protein-coupled receptor 139
External IDsOMIM: 618448; MGI: 2685341; GeneCards: GPR139
Orthologs
DatabasesNCBI: entry; OMA: entry
SpeciesHumanMouse
Entrez

124274

209776

Ensembl

ENSG00000180269

ENSMUSG00000066197

UniProt

Q6DWJ6

Q80UC8

RefSeq (mRNA)

NM_001002911
NM_001318483

NM_001024138

RefSeq (protein)

NP_001002911
NP_001305412

NP_001019309

Location (UCSC)Chr 16: 20.03 – 20.07 MbChr 7: 118.74 – 118.78 Mb
PubMed search
Wikidata
View/Edit HumanView/Edit Mouse

G-protein coupled receptor 139 (GPR139) is a G protein-coupled receptor that in humans is encoded by the GPR139 gene. It is coupled to the Gq/11 pathway, which is functionally opposite to the Gi/o inhibitory signaling of classical opioid receptors. It is evolutionarily ancient and highly conserved across vertebrate phylogenetic taxa, suggesting a fundamental role in neurophysiology. In humans, the receptor is exclusively expressed in the brain tissue, particularly in the medial habenula, septum, striatum, and hypothalamus.

Historically classified as an orphan receptor, activated only by L-tryptophan and L-phenylalanine in very high concentrations, GPR139 was deorphanized in 2025 as a novel, non-canonical opioid receptor specific to dynorphins, which selectively promote G protein activation of the receptor. It is proposed to function as a molecular homeostatic brake for excessive canonical opioid and D2 receptor signaling. Tryptamine is also a potent agonist of the GPR139 and has been reported to regulate sleep.

Research has shown that mice with loss of GPR139 experience schizophrenia-like symptomatology that is rescued with the dopamine receptor antagonist haloperidol and the μ-opioid receptor antagonist naltrexone.